Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nalmefene prodrug
- Development stage
- Phase 1
- Lead developer
- Nirsum Laboratories
- Modality
- Small Molecules
- Administration
- Injectable
01
Overview
NRS-033 is a second-generation, long-acting injectable opioid antagonist developed by Nirsum Labs for the treatment of opioid use disorder (OUD) and alcohol use disorder (AUD). It is a small molecule drug and functions as a prodrug of nalmefene, designed to improve therapeutic retention compared to existing therapies. The drug acts as an opioid receptor antagonist, blocking the effects of opioids at their receptors. As of early 2025, NRS-033 has completed Phase I clinical trials in the United States for opioid-related disorders and is entering Phase II development for both OUD and AUD. The product aims to address high relapse rates associated with current treatments by providing longer-lasting antagonism[1][3][4][8].
- Other names
- NRS 033NRS033NRS-033
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on nalmefene prodrug.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nalmefene prodrug.